This purpose of this study is to see if the investigational drug called Extended Release Guanfacine Hydrochloride (SPD503) is safe and effective for the treatment of Generalized Anxiety Disorder, Separation Anxiety Disorder or social phobia as compared to placebo in children aged 6-17 years old.

SPD 503 is available in the market under the trade name INTUNIV and has been approved by the FDA for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

There is a 25 percent chance that your child will not receive the active study drug. Study participation involves seven (7) weekly visits and three (3) bi-monthly visits over a period of up to 19 weeks.

Compensation up to $425.

For more information, call 919-681-0032.